Conference Calendar

March 14-18 - American Association of Orthopaedic Medicine Annual Meeting 2017

March 14-December 31 - Canaccord Genuity Musculoskeletal Conference

Complete Calendar »

Earnings Calendar

No Upcoming Events Scheduled
Complete Calendar »

Read our research via:
email art

Weekly Email

rss art


app icon


app store icon


Orthopedic and Dental Industry News Complete Archive »

Musculoskeletal News Roundup 18-Nov-10 BY LAUREN UZDIENSKI, NOVEMBER 18, 2010

Bacterin reported 3Q:10 revenues of $4.2 million, which compares to $1.4 million in 3Q:10. The company attributed their revenue growth to the implementation of a direct sales force in July 2009. The company reported a net loss of $9.0 million, or $0.26 per basic share, in 3Q:10, which compares to a net loss of $1.9 million, or $0.09 per basic share, in 3Q:10.

Medtronic completed the acquisition of Osteotech at $6.50 per share in cash for each share of Osteotech stock. The total transaction value was approximately $123.0 million.

Replication Medical received a $0.2 million Qualifying Therapeutic Discovery Project grant from the U.S. government to cover research expenses related to the GelStix, which is described as a matchstick-sized implant inserted into the intradiscal space without surgery. The GelStix is then said to "absorb bodily fluids and expand many times in volume to rehydrate and repressurize the disc."

RepRegen raised GBP 1.0 million ($1.6 million) in a financing round led by Imperial Innovations and included Longbow Capital and other investors. Funds will be used to further regulatory approvals, advance commercialization programs and prepare for relevant post-market clinical studies for StronBone, the company's bioactive glass.

SI-BONE received CE mark clearance to sell its iFuse Implant System, a minimally-invasive surgical device to treat the sacroiliac joint. The system consists of titanium implants coated with a porous plasma spray that the company says acts as an interference surface. The first EU training sessions were held in October and November in Salzburg, Austria.

Titan Spine received 510(k) clearance to market the Endoskeleton TO system, which consists of a line of interbody devices designed to be implanted with a PLIF approach. The Endoskeleton TO will be launched in December 2010.

Paradigm BioDevices filed a lawsuit in the U.S. District Court of Massachusetts against Viscogliosi Bros. LLC, Viscogliosi & Co, LLC, Paradigm Spine, LLC, Centinel Spine, Inc. and individually Anthony Viscogliosi and John Viscogliosi. The suit stems from the 2008 termination of Paradigm BioDevices' exclusive U.S. distribution rights of Surgicraft's STALIF TT spinal fusion devices.

Mazor Robotics announced the publication of results from a multi-center, retrospective study showing the company's SpineAssist robot to be clinically accurate in 98% of implant placements in spinal surgery. The company added that free-hand implant placements are documented in the literature to be misplaced in about 10% of cases. Further, the study demonstrated that SpineAssist contributes to significantly lower rates of misplaced screws and neurological deficits than free-hand procedures.

Amedica/US Spine signed an agreement with BioDlogics for the licensing and distribution of stem cell products indicated for spinal fusion, as an adhesion barrier and for nerve protection. The tissue would be formulated as a liquid injectable and as a structured barrier. The press releases notes that BioDlogics procures and processes human cellular and tissue-based products from the amniotic tissue of healthy, pre-screened live donors through scheduled caesarian births.

Titan Spine appointed Andrew Shepherd Vice President of Marketing. Prior to joining Titan Spine, Mr. Shepherd served as Vice President of Sales & Marketing for Impliant, Inc. He has also held sales, management, educational and strategic training positions within J&J subsidiaries DePuy Spine and Codman.

Email this to a colleague: